| Gefitinib | IC50 | 20.0 [1] |
| Gefitinib | Ki | 0.4 [1] |
| Erlotinib | IC50 | 30.0 [1] |
| Erlotinib | Ki | 0.1 [1], 45.0 [2] |
| Osimertinib | IC50 | 3.9 [1] |
| Osimertinib | Ki | 1.5 [1], 1.6 [2], 3.5 [3], 14.0 [4] |
| Lapatinib | IC50 | 12.0 [1] |
| N-(3-Bromophenyl)-6,7-dimethoxyquinazolin-4-amine | IC50 | 30.0 [1] |
| N-(3-Bromophenyl)-6,7-dimethoxyquinazolin-4-amine | Ki | 0.01 [1] |
| Rociletinib | IC50 | 20.0 [1] |
| Rociletinib | Ki | 1.7 [1], 1.8 [2], 21.0 [3], 74.0 [4], 303.0 [5] |
| WZ4002 | IC50 | 10.0 [1] |
| 4-[(3-Bromophenyl)amino]-6-acrylamidoquinazoline | IC50 | 2.0 [1] |
| Staurosporine | IC50 | 49.0 [1] |
| Afatinib | IC50 | 1.0 [1] |
| Canertinib | IC50 | 2.3 [1] |
| Pelitinib | IC50 | 39.0 [1] |
| N4-(3-Bromophenyl)quinazoline-4,6-diamine | IC50 | 44.0 [1] |
| Vandetanib | IC50 | 200.0 [1] |
| Sunitinib | IC50 | 172100.0 [1] |
| Tyrphostin A46 | IC50 | 10000.0 [1] |
| Tyrphostin A46 | Ki | 3500.0 [1] |
| 4-(4-Fluorophenyl)-5-pyridin-4-yl-2-(2,4,6-trichlorophenyl)pyrazol-3-amine | IC50 | 113.0 [1] |
| Neratinib | IC50 | 2.5 [1] |
| N-(3-Chloro-4-fluorophenyl)-6,7-dimethoxyquinazolin-4-amine | IC50 | 9.0 [1] |
| Ibrutinib | IC50 | 5.6 [1] |
| N4-(3-Chlorophenyl)quinazoline-4,6-diamine | IC50 | 200.0 [1] |
| Tyrphostin B42 | IC50 | 501.19 [1] |
| N4-(3-Bromophenyl)-N6-methylpyrido[3,4-d]pyrimidine-4,6-diamine | IC50 | 0.01 [1] |
| Tykerb | IC50 | 11.0 [1] |
| Semaxanib | IC50 | 100000.0 [1] |
| N-(4-((3-Bromophenyl)amino)quinazolin-6-yl)but-2-ynamide | IC50 | 2.5 [1] |
| Tyrphostin AG 538 | IC50 | 5000.0 [1] |
| 4-[(3-Bromophenyl)amino]-6,7-diaminoquinazoline | IC50 | 0.12 [1] |
| (E)-N-[4-(3-Bromoanilino)-3-cyanoquinolin-6-yl]-4-(dimethylamino)but-2-enamide | IC50 | 310.0 [1] |
| N-(3-Bromophenyl)-1H-pyrazolo[4,3-g]quinazolin-5-amine | IC50 | 0.44 [1] |
| N-[4-(3-Bromoanilino)-3-cyanoquinolin-6-yl]but-2-ynamide | IC50 | 940.0 [1] |
| N-[4-(3-Bromo-phenylamino)-3-cyano-quinolin-6-yl]-acrylamide | IC50 | 590.0 [1] |
| N-[3-[2-[4-(4-Acetylpiperazin-1-yl)-2-methoxyanilino]-5-(trifluoromethyl)pyrimidin-4-yl]oxyphenyl]prop-2-enamide | IC50 | 7.0 [1], 67.0 [2], 132.0 [3], 200.0 [4], 1034.0 [5] |
| Tyrphostin 47 | IC50 | 1310.0 [1], 2400.0 [2], 3000.0 [3], 7000.0 [4] |
| Tyrphostin 47 | Ki | 850.0 [1] |
| Dacomitinib | IC50 | 6.0 [1] |
| Tyrphostin AG 555 | IC50 | 700.0 [1] |
| Tyrphostin B48 | IC50 | 1250.0 [1] |
| Lavendustin c | IC50 | 30.0 [1], 150.0 [2], 2900.0 [3], 92000.0 [4] |
| (2e)-N-{4-[(3-Bromophenyl)amino]quinazolin-6-Yl}-4-(Dimethylamino)but-2-Enamide | IC50 | 10.0 [1] |
| 7-Amino-4-[(3-bromophenyl)amino]pyrido[4,3-d]pyrimidine | IC50 | 10.0 [1] |
| N-(3-Bromophenyl)-8H-pyrrolo[3,2-g]quinazolin-4-amine | IC50 | 0.44 [1] |
| Afatinib Impurity C | IC50 | 0.5 [1] |
| Dithiobis(1H-indoles) deriv. 4 | IC50 | 3300.0 [1], 7400.0 [2], 7600.0 [3], 100000.0 [4] |
| Dithiobis(1H-indoles) deriv. 4 | Ki | 19400.0 [1], 21200.0 [2] |
| 4-N-(3-Bromophenyl)pyrido[3,4-d]pyrimidine-4,6-diamine | IC50 | 0.13 [1] |
| 4-N-(3-Bromophenyl)-6-N,6-N-dimethylpyrido[3,4-d]pyrimidine-4,6-diamine | IC50 | 0.01 [1] |
| Unii-5IE92SK9EB | IC50 | 7.0 [1], 13.0 [2], 140.0 [3], 5100.0 [4] |
| Unii-5IE92SK9EB | Ki | 1600.0 [1] |
| N-[(3R,4R)-4-Fluoro-1-[6-[(1-methylpyrazol-4-yl)amino]-9-propan-2-ylpurin-2-yl]pyrrolidin-3-yl]prop-2-enamide | IC50 | 2.0 [1], 7.0 [2], 9.0 [3], 178.0 [4] |
| N-[(3R,4R)-4-Fluoro-1-[6-[(1-methylpyrazol-4-yl)amino]-9-propan-2-ylpurin-2-yl]pyrrolidin-3-yl]prop-2-enamide | Ki | 2.0 [1] |
| N-[(3R,4R)-1-[6-[(1,3-Dimethylpyrazol-4-yl)amino]-9-propan-2-ylpurin-2-yl]-4-fluoropyrrolidin-3-yl]prop-2-enamide | IC50 | 4.0 [1], 16.0 [2], 26.0 [3], 1450.0 [4], 10000.0 [5] |
| N-[(3R,4R)-1-[6-[(1,3-Dimethylpyrazol-4-yl)amino]-9-propan-2-ylpurin-2-yl]-4-fluoropyrrolidin-3-yl]prop-2-enamide | Ki | 17.0 [1] |
| 1-[(3R)-3-[4-Amino-3-(1-methylindol-3-yl)pyrazolo[3,4-d]pyrimidin-1-yl]piperidin-1-yl]prop-2-en-1-one | IC50 | 3.0 [1] |
| 1-[(3R)-3-(4-Amino-3-naphthalen-1-ylpyrazolo[3,4-d]pyrimidin-1-yl)piperidin-1-yl]prop-2-en-1-one | IC50 | 2.0 [1] |
| 1-[(3R)-3-(4-Amino-3-naphthalen-2-ylpyrazolo[3,4-d]pyrimidin-1-yl)piperidin-1-yl]prop-2-en-1-one | IC50 | 1.0 [1] |
| N-(4-(3-Bromoanilino)quinazolin-6-yl)-2-(perfluorophenoxy)-acetamide | IC50 | 49.8 [1] |
| N-[2-[2-(Dimethylamino)ethyl-methylamino]-5-[[6-(3-fluoroanilino)-1H-indazol-3-yl]amino]-4-methoxyphenyl]prop-2-enamide | IC50 | 1.0 [1] |
| N-[2-[2-(Dimethylamino)ethyl-methylamino]-5-[[6-(3-fluoroanilino)-1H-indazol-3-yl]amino]-4-methoxyphenyl]prop-2-enamide | Ki | 3.9 [1], 5.1 [2], 7.4 [3] |
| N-[2-[2-(Dimethylamino)ethyl-methylamino]-4-methoxy-5-[(5-naphthalen-2-yl-1H-indazol-3-yl)amino]phenyl]prop-2-enamide | IC50 | 1.1 [1], 2.2 [2], 8.1 [3] |
| N-[2-[2-(Dimethylamino)ethyl-methylamino]-4-methoxy-5-[(5-naphthalen-2-yl-1H-indazol-3-yl)amino]phenyl]prop-2-enamide | Ki | 28.0 [1], 105.0 [2], 147.0 [3] |
| N-[2-[2-(Dimethylamino)ethyl-methylamino]-4-methoxy-5-[[6-(1-methylindol-3-yl)-1H-indazol-3-yl]amino]phenyl]prop-2-enamide | IC50 | 1.5 [1], 4.8 [2], 9.3 [3] |
| N-[2-[2-(Dimethylamino)ethyl-methylamino]-4-methoxy-5-[[6-(1-methylindol-3-yl)-1H-indazol-3-yl]amino]phenyl]prop-2-enamide | Ki | 57.0 [1], 149.0 [2], 236.0 [3] |
| Genistein | IC50 | 1000.0 [1], 2600.0 [2], 25120.0 [3] |
| Dasatinib | IC50 | 20.0 [1], 180.0 [2], 322.0 [3], 2870.0 [4] |
| Crizotinib | IC50 | 1000.0 [1], 12500.0 [2], 1000000.0 [3] |
| N-(3-Chlorophenyl)-6,7-dimethoxyquinazolin-4-amine | IC50 | 0.31 [1], 0.32 [2], 5.0 [3], 6.0 [4], 120.0 [5] |
| Tyrphostin B56 | IC50 | 1100.0 [1], 3000.0 [2], 5000.0 [3], 5011.87 [4] |
| Cudc-101 | IC50 | 2.4 [1], 17.6 [2] |
| Poziotinib | IC50 | 1.3 [1], 2.2 [2], 3.2 [3], 4.2 [4], 4.4 [5] |
| Tyrphostin AG 698 | IC50 | 616.6 [1], 625.0 [2], 900.0 [3], 930.0 [4] |
| N-(3-Bromophenyl)quinazolin-4-amine | IC50 | 27.0 [1], 27.54 [2] |
| (E)-N-[4-(3-Bromoanilino)-3-cyanoquinolin-6-yl]but-2-enamide | IC50 | 1620.0 [1], 1621.81 [2], 1620317.04 [3] |
| N-[4-(3-Bromoanilino)-3-cyanoquinolin-6-yl]-4-methoxybut-2-ynamide | IC50 | 954.99 [1], 960.0 [2], 960063.59 [3] |
| N-[4-(3-Chloro-4-fluoro-phenylamino)-3-cyano-quinolin-6-yl]-2-morpholin-4-ylmethyl-acrylamide | IC50 | 2691.53 [1], 2700.0 [2], 2700225.29 [3] |
| (E)-N-[4-(3-Chloro-4-fluoroanilino)-3-cyanoquinolin-6-yl]-4-morpholin-4-ylbut-2-enamide | IC50 | 2290.0 [1], 2290.87 [2], 2290340.22 [3] |
| N-[4-(3-Bromoanilino)-3-cyanoquinolin-6-yl]-4-(2-methoxyethoxy)but-2-ynamide | IC50 | 930.0 [1], 933.25 [2], 930036.51 [3] |
| N-[4-(3-Bromoanilino)-3-cyanoquinolin-6-yl]-4-thiomorpholin-4-ylbut-2-ynamide | IC50 | 549.54 [1], 550.0 [2], 550047.25 [3] |
| (E)-N-[4-(3-Chloro-4-fluoroanilino)-3-cyanoquinolin-6-yl]-4-(dimethylamino)but-2-enamide | IC50 | 645.65 [1], 650.0 [2], 650129.69 [3] |
| 2-Hydroxy-5-[(2,5-dihydroxybenzyl)amino]benzoic acid methyl ester | IC50 | 600.0 [1], 1000.0 [2], 9000.0 [3], 24400.0 [4] |
| 4-N-(3-Bromophenyl)-7-N-methylpyrido[4,3-d]pyrimidine-4,7-diamine | IC50 | 0.13 [1], 16.0 [2] |
| 4-N-(3-Bromophenyl)-7-N,7-N-dimethylpyrido[4,3-d]pyrimidine-4,7-diamine | IC50 | 0.09 [1], 14.0 [2] |
| 4-N-(3-Bromophenyl)pyrido[3,2-d]pyrimidine-4,6-diamine | IC50 | 7.6 [1], 7.76 [2], 53.0 [3] |
| 4-N-(3-Bromophenyl)-6-N-methylpyrido[3,2-d]pyrimidine-4,6-diamine | IC50 | 3.1 [1], 3.16 [2], 20.0 [3] |
| 4-N-(3-Bromophenyl)-6-N,6-N-dimethylpyrido[3,2-d]pyrimidine-4,6-diamine | IC50 | 9.6 [1], 9.77 [2], 32.0 [3] |
| Tyrphostin deriv. 25 | IC50 | 560.0 [1], 600.0 [2], 5100.0 [3], 5128.61 [4], 20000.0 [5] |
| Tyrphostin deriv. 28 | IC50 | 880.0 [1], 900.0 [2], 7000.0 [3], 15000.0 [4], 15135.61 [5] |
| Tyrphostin deriv. 29 | IC50 | 1000.0 [1], 1300.0 [2], 14000.0 [3], 14125.38 [4], 15000.0 [5] |
| Tyrphostin deriv. 33 | IC50 | 2000.0 [1], 2300.0 [2], 10964.78 [3], 11000.0 [4], 20000.0 [5] |
| 2-Cyano-3-(4-hydroxy-3-methoxy-5-((phenylthio)methyl)phenyl)-2-propenamide | IC50 | 398.11 [1], 400.0 [2], 500.0 [3], 2900.0 [4], 12500.0 [5] |
| 6,7-Bis(3-morpholin-4-ylpropoxy)-N-[4-[(E)-prop-1-enyl]phenyl]quinazolin-4-amine | IC50 | 20.7 [1], 20.72 [2], 235.5 [3], 1000.0 [4], 2000.0 [5] |
| Mavelertinib | IC50 | 3.0 [1], 5.0 [2], 12.0 [3], 307.0 [4] |
| Mavelertinib | Ki | 13.0 [1] |
| N-[(3R,4R)-4-Fluoro-1-[6-[(3-methoxy-1-methylpyrazol-4-yl)amino]-9-propan-2-ylpurin-2-yl]pyrrolidin-3-yl]prop-2-enamide | IC50 | 1.0 [1], 2.0 [2], 5.0 [3], 160.0 [4] |